Skip to main content
. Author manuscript; available in PMC: 2018 Jan 1.
Published in final edited form as: Clin Cancer Res. 2016 Jun 27;23(1):193–203. doi: 10.1158/1078-0432.CCR-16-0040

Figure 1. The therapeutic effect of anti-CD20 treatment is CD8 T cell dependent.

Figure 1

(A) WT BALB/c mice (n = 6/group) or (B) BALB/c-nude mice (n = 6/group) were injected subcutaneously (s.c.) with 1.8*106 A20 cells and were treated with 100 μg of anti-mCD20 or 100 μg of hIgG (Ctrl) by i.p. on days 12 and 15 post A20 injection. This is the basic procedure for C to E. (C) A20-bearing BALB/c mice (n = 6/group) were treated as in A. CD8+ T-cell-depleting Ab (TIB210, 200 μg/mouse) was administered twice a week starting on day 11. (D) Eleven days after the final Ab treatment, draining lymph node (DLN) cells were collected, and the IFN-γ ELISPOT assay was performed with medium or irradiated A20 cell restimulation. Irradiated 4T1 cells were used as the control. (E) A20-bearing BALB/c mice (n = 6/group) were treated as in A. Mouse IFN-γ Ab (R4-6A2, 200 μg/mouse) was administered twice a week starting on day 11. The mean ± SEM values are shown. Two-tailed Student’s t test was used for statistical analysis.